Novavax to Participate in the FBR New Prescriptions Conference

GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the FBR Healthcare Series Conference New Prescriptions: Innovation in the Treatment of Diseases and Infections.

Conference details are as follows:

Date: Wednesday, April 20, 2016Time: 9:30 a.m. U.S. Eastern TimeLocation: J.W. Marriott Essex House, New York City

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
[email protected]
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

[email protected]
[email protected]
212-845-4271

You May Also Be Interested In

• Genco Shipping & Trading Limited Issues Open Letter to Shareholders Following Withdrawal by Diana Shipping Inc. of its Offer
• Start of Day Message
• Digital Heroes Surpasses 2,000 Brand Clients and Publishes 1,073 Shopify Buyer Guides as Agency Expands Global Shopify Development Operations